These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
137 related articles for article (PubMed ID: 27587202)
1. Cisplatin Analogues with an Increased Interaction with DNA: Prospects for Therapy. Hardie ME; Kava HW; Murray V Curr Pharm Des; 2016; 22(44):6645-6664. PubMed ID: 27587202 [TBL] [Abstract][Full Text] [Related]
2. The interaction of DNA-targeted 9-aminoacridine-4-carboxamide platinum complexes with DNA in intact human cells. Temple MD; Recabarren P; McFadyen WD; Holmes RJ; Denny WA; Murray V Biochim Biophys Acta; 2002 Apr; 1574(3):223-30. PubMed ID: 11997087 [TBL] [Abstract][Full Text] [Related]
3. The sequence selectivity of DNA-targeted 9-aminoacridine cisplatin analogues in a telomere-containing DNA sequence. Paul M; Murray V J Biol Inorg Chem; 2011 Jun; 16(5):735-43. PubMed ID: 21465324 [TBL] [Abstract][Full Text] [Related]
4. The potential of acridine carboxamide Pt complexes as anti-cancer agents : a review. Murray V; Chen JK; Galea AM Anticancer Agents Med Chem; 2014 Jun; 14(5):695-705. PubMed ID: 24102313 [TBL] [Abstract][Full Text] [Related]
5. Characterising the atypical 5'-CG DNA sequence specificity of 9-aminoacridine carboxamide Pt complexes. Kava HW; Galea AM; Md Jamil F; Feng Y; Murray V J Biol Inorg Chem; 2014 Aug; 19(6):997-1007. PubMed ID: 24827388 [TBL] [Abstract][Full Text] [Related]
6. CpG methylation increases the DNA binding of 9-aminoacridine carboxamide Pt analogues. Kava HW; Murray V Bioorg Med Chem; 2016 Oct; 24(19):4701-4710. PubMed ID: 27567075 [TBL] [Abstract][Full Text] [Related]
7. In vitro studies on the mechanisms of oxaliplatin resistance. Hector S; Bolanowska-Higdon W; Zdanowicz J; Hitt S; Pendyala L Cancer Chemother Pharmacol; 2001 Nov; 48(5):398-406. PubMed ID: 11761458 [TBL] [Abstract][Full Text] [Related]
8. The DNA binding properties of 9-aminoacridine carboxamide Pt complexes. Kava HW; Leung WY; Galea AM; Murray V Bioorg Med Chem; 2021 Jun; 40():116191. PubMed ID: 33965841 [TBL] [Abstract][Full Text] [Related]
9. Determination of cisplatin 1,2-intrastrand guanine-guanine DNA adducts in human leukocytes by high-performance liquid chromatography coupled to inductively coupled plasma mass spectrometry. Harrington CF; Le Pla RC; Jones GD; Thomas AL; Farmer PB Chem Res Toxicol; 2010 Aug; 23(8):1313-21. PubMed ID: 20666396 [TBL] [Abstract][Full Text] [Related]
10. The interactions of novel mononuclear platinum-based complexes with DNA. Johnson BW; Burgess MW; Murray V; Aldrich-Wright JR; Temple MD BMC Cancer; 2018 Dec; 18(1):1284. PubMed ID: 30577821 [TBL] [Abstract][Full Text] [Related]
11. Reversal of platinum drug resistance by the histone deacetylase inhibitor belinostat. To KK; Tong WS; Fu LW Lung Cancer; 2017 Jan; 103():58-65. PubMed ID: 28024697 [TBL] [Abstract][Full Text] [Related]
12. Synthesis, characterization, and biological evaluation of new tetrazole-based platinum(II) and palladium(II) chlorido complexes--potent cisplatin analogues and their trans isomers. Serebryanskaya TV; Yung T; Bogdanov AA; Shchebet A; Johnsen SA; Lyakhov AS; Ivashkevich LS; Ibrahimava ZA; Garbuzenco TS; Kolesnikova TS; Melnova NI; Gaponik PN; Ivashkevich OA J Inorg Biochem; 2013 Mar; 120():44-53. PubMed ID: 23305964 [TBL] [Abstract][Full Text] [Related]
13. Influence of cellular factors and pharmacokinetics on the formation of platinum-DNA adducts in leukocytes of children receiving cisplatin therapy. Veal GJ; Dias C; Price L; Parry A; Errington J; Hale J; Pearson AD; Boddy AV; Newell DR; Tilby MJ Clin Cancer Res; 2001 Aug; 7(8):2205-12. PubMed ID: 11489793 [TBL] [Abstract][Full Text] [Related]
14. Quantitative evaluation of cellular uptake, DNA incorporation and adduct formation in cisplatin sensitive and resistant cell lines: Comparison of different Pt-containing drugs. Corte-Rodríguez M; Espina M; Sierra LM; Blanco E; Ames T; Montes-Bayón M; Sanz-Medel A Biochem Pharmacol; 2015 Nov; 98(1):69-77. PubMed ID: 26352094 [TBL] [Abstract][Full Text] [Related]
15. Effect of lipophilicity of amylamine and amylglycine ligands on biological activity of new anticancer cisplatin analog. Safa Shams Abyaneh F; Eslami Moghadam M; Hossaini Sadr M; Divsalar A J Biomol Struct Dyn; 2018 Mar; 36(4):893-905. PubMed ID: 28335682 [TBL] [Abstract][Full Text] [Related]
16. Characterisation of the DNA sequence specificity, cellular toxicity and cross-linking properties of novel bispyridine-based dinuclear platinum complexes. Johnson BW; Murray V; Temple MD BMC Cancer; 2016 May; 16():333. PubMed ID: 27225032 [TBL] [Abstract][Full Text] [Related]
17. Platinum(IV)-nitroxyl complexes as possible candidates to circumvent cisplatin resistance in RT112 bladder cancer cells. Cetraz M; Sen V; Schoch S; Streule K; Golubev V; Hartwig A; Köberle B Arch Toxicol; 2017 Feb; 91(2):785-797. PubMed ID: 27307157 [TBL] [Abstract][Full Text] [Related]
18. DNA sequence selectivity of cisplatin analogues in intact human cells. Murray V; Whittaker J; McFadyen WD Chem Biol Interact; 1998 Mar; 110(1-2):27-37. PubMed ID: 9566723 [TBL] [Abstract][Full Text] [Related]
19. One-milliliter wet-digestion for inductively coupled plasma mass spectrometry (ICP-MS): determination of platinum-DNA adducts in cells treated with platinum(II) complexes. Yamada K; Kato N; Takagi A; Koi M; Hemmi H Anal Bioanal Chem; 2005 Aug; 382(7):1702-7. PubMed ID: 15959768 [TBL] [Abstract][Full Text] [Related]